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Abstract: Chronic low back pain (LBP) remains a challenging condition to treat, and especially to 
cure. If conservative treatment approaches fail, the current “gold standard” for intervertebral disc 
degeneration (IDD)-provoked back pain is spinal fusion. However, due to its invasive and destruc-
tive nature, the focus of orthopedic research related to the intervertebral disc (IVD) has shifted more 
towards cell-based therapeutic approaches. They aim to reduce or even reverse the degenerative 
cascade by mimicking the human body’s physiological healing system. The implementation of pro-
genitor and/or stem cells and, in particular, the delivery of mesenchymal stromal cells (MSCs) has 
revealed significant potential to cure the degenerated/injured IVD. Over the past decade, many re-
search groups have invested efforts to find ways to utilize these cells as efficiently and sustainably 
as possible. This narrative literature review presents a summary of achievements made with the 
application of MSCs for the regeneration of the IVD in recent years, including their preclinical and 
clinical applications. Moreover, this review presents state-of-the-art strategies on how the homing 
capabilities of MSCs can be utilized to repair damaged or degenerated IVDs, as well as their current 
limitations and future perspectives. 
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1. Introduction 
The Burden of Low Back Pain and Its Association with Intervertebral Disc Degeneration 
Being the leading cause of disability worldwide, low back pain (LBP) provokes ag-
ony in up to 637 million people worldwide [1]; it accounts for more lost workdays than 
any other musculoskeletal disorder in the USA, and in Europe, LBP is the most prevalent 
reason for premature retirement and medically certified sick leave [2–4]. Even though LBP 
occurs predominantly among female individuals between the ages of 40 and 80 years, no 
age group is spared from LBP, and also countless children worldwide suffer from this 
condition [5]. In addition to being a personal struggle for each individual sufferer com-
bined with a decreased quality of life, LBP is also responsible for a remarkable economic 
burden, causing expenses between $100 and $200 billion per year in the US alone [6]. 
Strikingly, two-thirds of these expenses are indirect costs, primarily due to lost wages [6]. 
Even though most back pain episodes start all of a sudden and usually are of short dura-
tion, they can also become chronic [3,7]. As a result, the burden of LBP remains long term 
or even a lifetime [8]. The causes of LBP are manifold; it can be idiopathic or initiated by 
Citation: Croft, A.S.; Illien-Jünger, 
S.; Grad, S.; Guerrero, J.; Wangler, S.; 
Gantenbein, B. The Application of 
Mesenchymal Stromal Cells and 
Their Homing Capabilities to  
Regenerate the Intervertebral Disc. 
Int. J. Mol. Sci. 2021, 22, 3519. 
https://doi.org/10.3390/ijms22073519 
Academic Editor: Inbo Han 
Received: 27 February 2021 
Accepted: 26 March 2021 
Published: 29 March 2021 
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional 
claims in published maps and insti-
tutional affiliations. 
 
Copyright: © 2021 by the authors. 
Licensee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (http://cre-
ativecommons.org/licenses/by/4.0/). 
Int. J. Mol. Sci. 2021, 22, 3519 2 of 18 
 
 
vertebral fractures, infections, spinal tumors, or by intervertebral disc degeneration (IDD) 
[3,9]. In particular, the latter deserves attention, as IDD is the main contributor to LBP [10]. 
However, in order to understand the possible correlations between IDD and LBP, one 
should consider the general structure of a healthy intervertebral disc (IVD) and how a 
pathophysiological development of the IVD can potentially lead to this disease. 
IVDs are the biggest avascular organs in the human body, and they are essential for 
the spine to move with six degrees of freedom [11,12]. Additionally, due to its unique 
architecture, an IVD is also an excellent shock distributor. This feature is mainly based on 
the IVD’s highly hydrated core, the nucleus pulposus (NP), which consists of up to 88% 
water [13]. The water is retained in the NP’s extracellular matrix (ECM) by negatively 
charged proteoglycans, which are structured by a network of collagen type II (COL2) fi-
bers [14]. The NP is surrounded and held in place by the resilient annulus fibrosus (AF), 
a tissue rich in collagen type I (COL1) fibers organized in concentric lamellae [15]. Finally, 
the NP and AF are enclosed by two hyaline cartilaginous endplates (CEP) on superior and 
inferior sites [15]. A physiologically healthy IVD is characterized by a well-balanced mi-
croenvironment, which is defined by low oxygen levels, high mechanical stress, high os-
motic pressure, and low pH [16]. 
Due to the IVD’s avascular nature, its cells depend on the blood vessels’ nutritional 
supply at the IVD margins [17]. Hence, a reduction in the supply of nutrients has been 
correlated with IDD [18]. This cut of essential nutrients can be caused by blocked capillar-
ies near the IVD or calcified CEPs, preventing the supplements from properly diffusing 
into the IVD [17]. Consequently, a lack of nutrients can be responsible for changes in the 
IVDs catabolic and anabolic turnover, cause dehydration, and lead to an aberrant produc-
tion of pro-inflammatory cytokines [19,20]. As a result, these cytokines can initiate inflam-
mation, promote vascular and nerve ingrowth into the IVD, induce pain, or even increase 
the risk of herniation (Figure 1) [20–23]. In addition to the lack of nutrient diffusion into 
the IVD, other risk factors such as excessive mechanical stress, smoking, trauma, and un-
favorable genetic predispositions have been correlated with IDD [1]. In the past, multiple 
studies have confirmed that many signs of IDD, i.e., an anterior or posterior bulge of the 
IVD, an insufficient blood supply, or a decreased signal intensity of the NP in a T2-
weighted image, are correlated with an increased risk of developing LBP [18,24]. Never-
theless, the exact cause of IDD and its relation to LBP are still under investigation. 
 
Figure 1. (a) Scheme of a cross-section of a healthy intervertebral disc (IVD) with its three tissue 
types: the nucleus pulposus (NP) in the center, surrounded by the annulus fibrosus and enclosed 
by two cartilaginous endplates. (b) Degenerated inflamed IVD characterized by nerve ingrowth, 
vascular ingrowth, reduced height, and herniation of the NP through the AF. 
There are many options to treat LBP, yet none of them come without any drawbacks 
or limitations. Acute or subacute conditions are usually treated non-invasively and pref-
erably non-pharmacologically [25]. Recommended therapies include acupuncture [26,27], 
physical therapy [28], exercise or superficial heat [29]. Additionally, for patients who suf-
fer from chronic LBP, non-pharmacological treatments are usually considered first [25]. If 
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these treatment options fail to reduce symptoms, pharmacological therapies are consid-
ered. They include the application of non-steroidal anti-inflammatory drugs (NSAIDs), 
acetaminophen, or opioids [29]. Nonetheless, in the case of inadequate response to con-
servative therapies, more invasive interventions are often required. Currently, the “gold-
standard” surgery to treat chronic LBP associated with IDD is a discectomy, followed by 
spinal fusion [30]. In brief, the degenerated IVD is removed, and the cavity between the 
adjacent vertebral bodies is replaced by a cage containing bone grafts or substitutes that 
can be supplemented with osteogenic inductive growth factors such as bone morphoge-
netic protein 2 (BMP2) to induce ossification [31,32]. Then, pedicle screws are inserted to 
improve the mechanical stability and to immobilize the adjacent vertebral bodies (Figure 
2) [33].  
 
Figure 2. Drawing of the process of achieving spinal fusion: (a) the degenerated disc diagnosed by 
means of imaging, (b) discectomy of the degenerated disc, (c) stabilization of the spine by inser-
tion of a cage (to maintain the disc height as a spacer) and the addition of an osteoconductive 
and/or osteoinductive filler material; optionally, BMP2 may be added, coupled with or without a 
biomaterial. 
Nonetheless, the efficacy of spinal fusion to reduce patient’s pain and disability is 
controversial. In the past, multiple studies have reported that spinal fusion is not more 
effective than non-surgical care for patients suffering from chronic LBP [34,35]. Therefore, 
the focus of ongoing IVD research has shifted increasingly towards regenerative ap-
proaches aiming to slow down or even reverse the ongoing degenerative cascade. The 
degenerative environment has to be stabilized to achieve this goal and eventually shifted 
towards the IVD’s physiological condition. Potential strategies include (i) blocking of pro-
inflammatory cytokines/proteinases in the ECM, (ii) reverse the gene expression of pro-
inflammatory cytokines/proteinases in the resident disc cells, or (iii) stimulating resident 
disc cells to produce novel ECM [36]. However, IVD degeneration is also associated with 
cell death resulting in a lack of regenerative capacity. Therefore, the application of addi-
tional cells into the degenerative environment has been introduced as a potential strategy 
to support regeneration [36]. A promising approach to induce IVD regeneration could be 
the use of progenitor cells such as the recently discovered NP cells that are positive for 
Tie2 marker (aka. angiopoietin-1 receptor) and disialoganglioside 2 (GD2) [37], as well as 
the use of stem cells such as induced pluripotent stem cells (iPSCs) [38]. Yet, the applica-
tion of mesenchymal stromal cells (MSCs) has been studied most extensively with regard 
to IVD regeneration [36,39–41]. 
For this reason, the purpose of this narrative literature review is to show the achieve-
ments and progress made on MSC-based therapy with the eventual aim to regenerate 
damaged and/or degenerated IVDs. A particular focus of this review is targeted on the 
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state-of-the-art strategies of MSC homing into IVDs, their potential, but also their current 
limitations for cell-based therapies. 
2. Application of Mesenchymal Stromal Cells for IVD Repair 
The sources of MSCs in the human body are manifold. In addition to the bone mar-
row, MSCs have been found in the cord blood, peripheral blood, adipose tissue, fetal tis-
sue, and the liver [42]. It has been shown for many years now that MSCs have multipotent 
characteristics enabling them to differentiate towards lineages of mesenchymal tissues 
[43,44]. Moreover, MSCs are also believed to secrete a broad spectrum of bioactive factors 
to regulate the microenvironment at the site of action, referred to as “trophic activity” [45]. 
These factors can further stimulate cell proliferation of endogenous stem or progenitor 
cells, enhance the expression of ECM proteins, downregulate the expression of pro-in-
flammatory cytokines and inhibit apoptosis and scarring of the remaining tissue [45–47]. 
2.1. Preclinical Studies with MSCs 
Due to these notable characteristics, research groups worldwide have tried to incor-
porate these features to regenerate the IVD (Table 1). Therefore, researchers either aim to 
differentiate MSCs into IVD-like cells and/or make use of MSC “trophic activity”. For ex-
ample, Stoyanov et al. looked at approaches for directing bone marrow-derived MSCs 
into a NP-cell-like phenotype [48]. They demonstrated that MSCs cultured in a hypoxic 
environment and supplemented with growth/differentiation factor 5 (GDF5) responded 
with an upregulation of IVD ECM related genes (aggrecan (ACAN), COL2) and NP mark-
ers (cytokeratin 19 (KRT19), forkhead box F1 (FOXF1), carbonic anhydrase 12 (CA12)). To 
a lesser extent, this was also seen when co-culturing the MSCs with bovine NP cells. Con-
sequently, they concluded that MSCs can acquire an NP-cell-like phenotype and can 
therefore be considered for IVD regenerative therapy. A similar approach to stimulate 
IVD-cell-like differentiation of MSCs with exogenously supplemented growth factors was 
documented by Clarke et al. [49]. They discovered that in addition to GDF5, transforming 
growth factor-beta 3 (TGF-β3) and in particular growth/differentiation factor 6 (GDF6) 
significantly increased the expression of the NP marker genes cytokeratin 8 (KRT8), cy-
tokeratin 18 (KRT18), KRT19, FOXF1, and CA12 as well as the production of glycosamino-
glycans (GAG) in MSCs. 
Table 1. Overview of reviews on preclinical studies about the application of MSCs for IVD regeneration published in the 
past five years. PubMed search with following query box: (((MSC) OR (mesenchymal stem cell)) OR (mesenchymal stro-
mal cell)) AND ((intervertebral disc repair) OR (intervertebral disc regeneration)) Filters: Review, Systematic Review, in 
the last 5 years. Reviews with a focus on clinical trials were excluded. The search on PubMed was conducted on January 
14, 2021. 
Study Design Outcomes 
Refer-
ences 
Reviewing current uses and potential applica-
tions of MSCs in orthopedic surgery. 
MSCs can be used for treating musculoskeletal diseases. Further research is needed to 
evaluate the safety and effectiveness of MSC treatment in orthopedics. 
[50] 
Reviewing current cell-based therapies for treat-
ing IDD, with an emphasis on endogenous repair 
strategies. 
Intradiscal cell injections show promising results to reduce LBP. Endogenous repair with 
growth factors and chemokines has the potential to overcome hurdles of cell-based thera-
pies. 
[36] 
Reviewing current knowledge about IDD and 
discussing recent advancements made with the 
GDF family for IVD regeneration. 
GDF family members can stimulate anabolic processes when delivered to NP cells and 
promote NP-like differentiation when delivered to MSCs. 
[51] 
Reviewing characteristics and potency of progeni-
tor cells in different IVD compartments.  
IVD progenitor cells show a trilineage differentiation potential and express typical MSC 
markers. Aging and a degenerated microenvironment affect the fate of IVD progenitor 
cells. 
[52] 
Reviewing the successes, drawbacks, and the fail-
ures of stem cell-based regenerative medicine ap-
proaches to repair IDD. 
MSC-based treatments for IDD are on the rise and many of them look promising. Never-
theless, it remains important to understand the fate and contribution of these cells and 
consequently to promote a safer outcome for stem cell-based approaches. 
[53] 
Researchers and clinicians discuss the pros and 
cons of MSC treatment for IVD regeneration. 
Preclinical trials using MSCs for IVD regeneration look promising because of MSC prolif-
eration characteristics, anabolic functionality and inflammation-modulatory properties. 
[54] 
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Reviewing mechanisms of endogenous repair 
during IDD. 
Endogenous stem/progenitor cell-based therapy is a promising approach for IDD. Biomi-
metic peptide biomaterials with signaling molecules can be designed to facilitate the sur-
vival and migration of IVD stem/progenitor cells. 
[55] 
Reviewing strategies for IVD repair using bioscaf-
folds and MSCs. 
Preclinical studies with ovine and canine MSCs show impressive results for IVD repair. 
The authors also hypothesize that combined therapeutic approaches using biomaterial 
and cell-based therapies promise notable breakthroughs in IVD repair in the near future. 
[56] 
Reviewing the therapeutic potential of MSC-de-
rived and IVD-derived extracellular vesicles for 
IDD. 
MSC-derived extracellular vesicles promote ECM synthesis, IVD cell proliferation, and 
reduce inflammation and apoptosis. 
[57] 
Reviewing stem cell-based treatments, the molec-
ular machinery and signaling pathways responsi-
ble for cartilage and IVD regeneration. 
MSC-based therapies show a significant potential to revolutionize the treatment of carti-
lage defects and IDD. However, there are still many hurdles associated with isolating, ex-
panding, differentiating, and preconditioning MSCs for transplantation into degenerated 
joints and IVDs. 
[58] 
Reviewing current stem cell therapies to treat dis-
cogenic LBP. 
Preliminary animal models have shown the great potential of MSC implantation in order 
to restore the ECM and regenerate the IVD. 
[59] 
Reviewing different stem cell-based treatments 
for IDD. 
The transplantation of adult stem cells has repeatedly shown to help regenerate the IVD’s 
ECM. However, the efficacy of adult stem cell transplantation for IDD treatment is still 
unclear and therefore needs further investigation. 
[60] 
Reviewing different stem cell types used as a cell-
based therapy for IVD regeneration. 
Adult stem cell therapy shows promise for the treatment of IDD. Recent studies have 
demonstrated the effectiveness of autologous MSC transplantation for IVD regeneration 
in reproducible animal models. 
[61] 
Reviewing characteristics of healthy and degener-
ated IVD microenvironments and their influence 
on IVD and MSC biological activity and viability. 
IDD causes an aggravation of the hostile microenvironment for tissue repair and cell sur-
vival in the IVD. However, intradiscal cell therapy with MSCs has the potential to regen-
erate the IVD and to reverse the changes of IDD. 
[41] 
Reviewing the latest advances in repairing degen-
erated IVDs using MSCs, pluripotent stem cells, 
and NP progenitor cells. 
Various animal models have shown that intradiscally transplanted MSCs generally fail to 
survive and engraft into the IVD niche, whereas pluripotent stem cells and NP progenitor 
cells can survive successfully. 
[62] 
Abbreviations: IVD: intervertebral disc, MSC: mesenchymal stromal cell, IDD: intervertebral disc degeneration, LBP: low 
back pain, GDF: growth and differentiation factor, NP: nucleus pulposus, AF: annulus fibrosus, PAX: paired box, SHH: 
sonic hedgehog signaling molecule, SOX: SRY-Box transcription factor, FOXA: forkhead box, and ECM: extracellular ma-
trix. 
MSCs in combination with hydrogels or scaffolds have also been a popular option 
for tissue engineering strategies. Scaffolds ideally mimic the tissue and provide structural 
support for cell attachment and/or proliferation as well as ECM accumulation [63]. For 
instance, Frauchiger et al. [64] used genetically engineered silk fleeces functionalized ei-
ther with GDF6 or TGF-β3 and seeded the silk with human bone marrow-derived MSCs. 
They demonstrated the high biocompatibility of silk for MSCs, whereby MSCs tended to 
differentiate towards an NP-like phenotype under these conditions. Moreover, many tis-
sue engineering strategies for IVD repair include the combined usage of MSCs with hy-
drogels. For example, Peroglio et al. [65] investigated the differentiation of human MSCs, 
which were embedded into a thermo-reversible hyaluronan-based hydrogel. They 
showed that MSCs seeded in this hydrogel and subsequently delivered into a bovine IVD 
showed enhanced disc-like differentiation than respective cells that were first pre-differ-
entiated with various growth factors and then implanted into the IVD. Furthermore, 
MSCs seeded in the hyaluronan hydrogel responded with a significant upregulation of 
COL2, SOX9, and a cluster of differentiation 24 (CD24) compared to the culture within 
alginate, indicating noticeable IVD-like differentiation of MSCs.  
A different kind of hydrogel has been tested by Zhang et. al, consisting of a combined 
triple interpenetrating network made of dextran, chitosan, and teleostean [66]. In combi-
nation, the three components form a stable hydrogel that mimics the mechanical proper-
ties of NP tissue. The objective of the in vivo study was to inject this hydrogel with and 
without the addition of MSCs into the NP of degenerated goat lumbar IVDs and to eval-
uate its therapeutic effect. Two weeks after treatment, a significant improvement in the 
IVD’s height was visible compared to the untreated controls as well as enhanced histolog-
ical conditions. The authors state that the combined treatment with MSCs and hydrogel 
generally evoked a greater therapeutic effect than the hydrogel alone. Only tumor necrosis 
factor-alpha (TNF-α) expression levels were less favorable in the combined condition. 
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Recently, an ambitious study was conducted by Sun et al. with the approach of using 
an anatomically correct 3D printed IVD scaffold made of different biomaterials, incorpo-
rated growth factors, and MSCs to replace a defective IVD [67]. In brief, the core and NP 
analogue consisted of a hydrogel mixed with bone marrow-derived MSCs and TGF-β3. 
The AF’s printing material was composed of the same components as the NP, but connec-
tive tissue growth factor (CTGF) was added. To ensure sufficient mechanical support for 
the scaffold, a framework made of polycaprolactone (PCL) was printed. In vitro testing 
revealed high cell viability levels (up to 99%) after seven days of culture. Furthermore, 
MSCs in the scaffold’s “NP” core showed significantly upregulated levels of ACAN and 
COL2 compared to controls, and the cells printed into the surrounding “AF” region ex-
pressed significantly more COL1, suggesting differentiation into AF-like cells. 
2.2. Clinical Studies with MSCs 
MSCs are very attractive from a clinical perspective as they can be isolated safely 
from the patient’s tissue and because of their negligible immunogenicity [68]. For these 
reasons, both autologous and allogeneic transplantations are enabled without the need 
for immunosuppressive drugs and with little ethical dispute [68]. In the past, a couple of 
clinical studies with predominantly positive outcomes have been carried out, in which 
MSCs were used to improve LBP associated with IDD [59,69]. In a pilot study by Orozco 
et al., ten patients diagnosed with lumbar disc degeneration and suffering from chronic 
LBP were injected with 10 million autologous bone marrow-derived MSCs per IVD [70]. 
Three months after the surgery, lumbar pain and disability were strongly reduced in 85% 
of the patients. Even after six and twelve months of follow-up, moderate improvements 
could be observed, including a significant increase in the IVD’s water content [70]. Nev-
ertheless, the treatment did not manage to restore the IVD’s height. A recent randomized 
controlled study including 24 patients diagnosed with lumbar disc degeneration investi-
gated the effect of intradiscal MSC injection. Patients were either treated with an injection 
of 25 million allogeneic bone marrow-derived MSCs per IVD or with a sham infiltration 
within the paravertebral musculature for the controls [71]. One year after surgery, the 
MSC-treated patients showed a significant reduction in pain in the lumbar region, re-
duced disability, and a decreased Pfirrmann grade. On the other hand, the control group 
did not show any amelioration of lumbar pain nor any improvements of disability, and 
the Pfirrmann grade even worsened significantly after one year. Favoring results regard-
ing the treatment of culture-expanded MSCs were also found in a pilot study by Centeno 
et al. [72]. The study analyzed prospectively collected data up to seven years from 33 pa-
tients suffering from LBP and diagnosed with a posterior bulge of the IVD. All patients 
received treatment with an injection of autologous MSCs. As a result, LBP remained con-
sistently lower than pretreatment, and for 85% of the patients, a reduction in the IVD bulge 
size was noticed. In addition, no safety issues such as infection, tumor growth, or death 
were recorded. Table 2 summarizes the published clinical studies related to intradiscal 
MSC transplantation. 
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Table 2. Published clinical studies related to intradiscal transplantation of MSCs. 










Injection of autologous 
BM-derived MSCs into 
the IVD. 
(1) IDD with posterior IVD bulge, (2) radicular 
pain, (3) failed conservative treatment, (4) failed 
interventional therapy, (5) patient refuses to pur-
sue surgical option 
33 N/A 6 years 
Three patients reported. No 
serious adverse events. Im-
proved SANE numeric pain 
score. 85% of patients 
showed reduced IVD bulge 
size. 
[72] 
Injection of autologous 
stromal vascular fraction 
containing adipose tis-
sue-derived MSCs to-
gether with platelet rich 
plasma. 
(1) Between 19 and 90 years of age, (2) LBP after 
failed conservative treatment for 6 months, (3) fi-
brous ring able to hold the cell implantation 
15 30–60 × 106 
6–12 
months 
Significant improvement in 
flexion, VAS, PPI, and pain. 
Positive trends for ODI and 
BDI. No severe adverse 
events were observed. 
[73] 
Injection of autologous 
BM-derived cultured in a 
hypoxic environment. 
(1) Between 18 and 65 years of age, (2) IDD and 
failed conservative treatment, (3) significantly 
functional disability due to pain, (4) painful annu-
lar fissures and low pressure positive discogra-
phy 
5 15.1–51.6 × 106 
4–6 
years 
No adverse events were re-
ported. Improvement in 
mobility, strength, and 
post-stem cell treatment. 
[74] 
Injection of adipose tis-
sue-derived MSCs com-
bined with hyaluronic 
acid derivates. 
(1) Between 10 and 70 years of age, (2) LBP for at 
least 3 months, (3) VAS ≥ 4, (4) ODI ≥ 30, (5) Pfirr-
mann’s grade III–IV, (6) IDD confirmed by dis-
cography 
10 
20 × 106 (n = 5) 




No adverse events were ob-
served. Improvement in 
VAS and ODI. Elevated 




Injection of allogeneic 
BM-derived MSCs into 
the IVD compared to 
sham injection. 
(1) IDD and remaining LBP after conservative 
treatment >6 months, (2) fibrous ring able to hold 
the cell implantation, (3) decrease in disc height 
>20%, (4) no spinal infection, (5) absent preg-
nancy in fertile women 
24 25 × 106 
12 
months 
Procedure was feasible and 
safe. Improved algofunc-
tional indices and Pfirr-
mann’s grade with MSC-
treated patients. 
[71] 
Injection of autologous 
BM-derived MSCs into 
the IVD. 
(1) Centralized chronic LBP for ≥6 months, (2) 
non-operative treatment for 3 months without 
resolution, (3) Pfirrmann’s grade 4–7, (4) Modic 
grade II change or less, (5) decrease in disc height 
<30%, (6) ODI ≥ 30/100 (7) VAS ≥ 4/10 
26 5426 CFU-F 3 years 
Improvement in VAS and 
ODI. 40% showed improve-
ment on Pfirrmann’s grade 
despite the relatively low 
number of CFU-F. 
[76] 
Injection of autologous 
BM-derived MSCs into 
the IVD. 
(1) Decrease in disc height >50%, (2) no spinal in-
fection, (3) stages 2, 3, and 4 of Adams, (4) LBP 
with IDD of one or two IVDs after conservative 
treatment for over 6 months, (5) No spinal infec-
tion 
10 10 ± 5 × 106 
12 
months 
85% of pain and disability 
improvement. Elevated wa-
ter content but no height re-
covery in IVDs. 
[70] 
Transplantation of a col-
lagen sponge containing 
autologous BM-derived 
MSCs into the IVD. 
(1) IDD confirmed with MRI, (2) vacuum phe-
nomenon, (3) IVD instability, (4) pressure and 
spontaneous pain at level of degenerated IVD, (5) 
failed conservative treatment 
2 N/A 2 years 
Enhanced pain scores and 
increased water content in 
the IVD. 
[39] 
Abbreviations: IVD: intervertebral disc, MSC: mesenchymal stromal cell, BM: bone marrow, LBP: low back pain, IDD: 
intervertebral disc degeneration, VAS: visual analogue scale, ODI: Oswestry Disability Index, PPI: present pain intensity, 
BDI: Beck Depression Inventor, CFU-F: colony forming unit -fibroblasts, SANE: Single Assessment Numeric Evaluation, 
and MRI: magnetic resonance imaging. 
Given the promising results observed with intradiscal cell injection, one can intui-
tively state that the best option for stem cell delivery into the IVD would be via needle 
injection. The main advantage is that a fixed number of cells can be precisely injected to 
the desired site of action. However, there are some considerable downsides. One problem 
of direct injection into the IVD is that the puncture causes trauma to the IVD to some 
extent and can therefore further aggravate its degenerated state [77,78]. Strikingly, multi-
ple studies have used needle puncture as a model for degenerated IVDs [79,80]. An addi-
tional disadvantage of MSC injection is that the cavity created by the needle can enable 
the cells to reflux out of the IVD. Not only will this cause a loss of MSCs at the place where 
the regeneration or treatment would be desired, but escaped cells can also induce the ad-
verse formation of osteophytes by altering the CEP tissue [81]. Furthermore, MSCs drawn 
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from their native environment are suddenly exposed to the harsh environment of an IVD 
after injection, which leaves cells only a little time to adapt to these new surroundings. 
Although the survival rate of post-transplanted MSCs is uncertain, it is believed that most 
of these cells do not survive long term in a degenerated IVD. Consequently, this results in 
an accumulation of necrotic and apoptotic cell debris and thus may have detrimental ef-
fects on IVD homeostasis [82]. 
2.3. MSC Homing into an IVD 
Because of the mentioned issues associated with direct cell injection, extensive efforts 
have been made to find alternative options for delivering MSCs into the IVD. In the last 
decade, great emphasis has been placed on the possibility of homing exogenous and en-
dogenous MSCs into the IVD. Homing of MSCs is known as a process where cells are 
recruited from their initial niche to injured or pathological tissue [83]. Thereby, cells are 
mobilized into the peripheral bloodstream and migrate to the damaged tissue or organ 
[84,85]. Bone marrow-derived MSCs are known to be well capable of homing to numerous 
injured sites in the body such as myocardial infarction [86,87], traumatic brain injury [88], 
nephropathy [89], lung injury [90], bone fractures [91] and degenerated IVDs [92,93]. 
However, knowledge about the exact process and mechanism of how MSCs are mobilized 
and guided to the effector location is still incomplete. Nevertheless, it is strongly sus-
pected that MSCs are navigated by multiple cell-signaling molecules and that the injured 
tissue itself expresses distinctive receptors or ligands to promote the infiltration of MSCs 
into the affected area [94]. To study this migration potential, Ponte et al. compared the in 
vitro migration capacity of bone marrow-derived MSCs through Transwell dishes under 
the influence of 16 growth factors and chemokines [95]. Before the migration assays were 
started, part of the cell population was preincubated either with TNF-α or interleukin-1β 
(IL-1β) to assess the impact of inflammatory cytokines on the migration capacity. They 
concluded that many growth factors and chemokines attracted a significant amount of 
unstimulated MSCs; though, growth factors were generally more efficient than chemo-
kines, the most effective ones being insulin-like growth factor-1 (IGF-1) and platelet-de-
rived growth factor-AB (PDGF-AB). Interestingly, cells that had initially been incubated 
with TNF-α increased their sensitivity for many chemokines, but only for one single 
growth factor tested. Here, the chemokines with the most potent effect on MSCs were 
RANTES (aka. CCL5), macrophage-derived chemokine (MDC), and stromal cell-derived 
factor-1 (SDF-1) [95]. In particular, SDF-1 (aka. CXCL-12) and its receptor C-X-C chemo-
kine receptor type 4 (CXCR4) have been identified to play an essential role in homing of 
multiple cell types [96]. In a former study, an injectable hydrogel based on hyaluronan-
poly(N-isopropylacrylamide) and supplemented with SDF-1 was used to recruit human 
MSCs in induced degenerated IVDs ex vivo [97]. The MSCs were applied onto the end-
plate of the organ cultured IVDs. The investigators showed that IVDs injected with SDF-
1 together with the hydrogel not only attracted significantly more MSCs than IVDs treated 
with the hydrogel only, but the migration distance covered in the IVD was also signifi-
cantly greater in these samples. Additionally, they also found that the migration of MSCs 
from younger donors was noticeably higher than the migrating distance of older ones. 
In another study, Pattappa et al. performed a proteomic analysis to identify the chem-
oattractants released by degenerated IVDs, which would enable MSCs to home into the 
tissue [98]. Therefore, IVDs were cultured in a bioreactor that simulated either physiolog-
ical or degenerative conditions for the IVDs (Figure 3). They found that RANTES, CXCL6, 
and IL-1β concentrations were elevated in the degenerated IVD’s media compared to the 
physiological conditions, whereby only the increase in RANTES was significant. Further-
more, a Boyden chamber assay was used to evaluate the chemoattractive properties of 
IVD-secreted RANTES. Here, depletion of RANTES in the IVD conditioned medium sig-
nificantly decreased the number of migrated MSCs in the chamber and revealed that this 
chemokine is a key chemoattractant for MSCs in degenerated IVDs [98]. 
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Based on the findings that RANTES could attract MSCs, Wangler et al. examined the 
subpopulation of cells that were mainly involved in the homing process in degenerated 
IVDs [99]. After characterizing the gene expression profile and the surface protein level of 
MSCs that migrated towards RANTES, they found that 60–90% of all migrated cells ex-
pressed the surface marker cluster of differentiation 146 (CD146). MSC subpopulations 
with CD146 as a surface marker were associated with a greater homing potential both in 
vitro and in organ culture using a bioreactor to either simulate physiological loading on 
IVDs or to induce its degeneration by applying high-frequency loading on the IVDs. 
Moreover, CD146-positive cells also showed an increased production of GAG when cells 
were cultured as pellets. Surprisingly, homing or injection of CD146-negative cells re-
sulted in a higher sulphated GAG synthesis rate than CD146-positive cells in an IVD organ 
culture model [99]. 
 
Figure 3. The principles of testing MSC homing in mechanically and/or nutritionally stressed 
IVDs. (a) Principle of homing using in vitro Boyden chamber assays (b) Testing of homing in 3D 
organ culture models (c) Evidence from in vivo animal models. Inlet 1: confocal laser scanning 
pictures (cLSM) of MSC homing experiment with differently labeled MSCs (green, red, and yel-
low) that were added at various time points during the experiment (A) a transverse section of a 
bovine IVD without endplates (B–D) close-up pictures at the outer AF (based on Illien-Jünger et al. 
[93]) Inlet 2: fluorescent image illustrating single stained MSCs in the outer periphery of the AF 
after 12 weeks post-injection, 10× magnification (based on Sakai et al. [92]). Inlet 2 was reproduced 
with copyright approval from the publisher. 
Knowing that MSCs can be attracted by growth factors and chemoattractants, which 
are predominantly released by degenerated IVDs, the question that arises is: how effi-
ciently are MSCs able to migrate into the affected IVD if they are released into the blood-
stream from their initial storage location? Or in relation to cell therapy, how well do MSCs 
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migrate to a degenerated IVD and contribute to its regeneration if they are injected intra-
venously? To address this question, Tam et al. compared the regeneration of degenerated 
IVDs following systemic or intradiscal MSC application [100]. Thereby, they used a mouse 
model in which IDD was induced by needle puncture, and multipotent stem cells derived 
from human umbilical cord blood to induce regeneration. First, they showed that the 
homing ability of intravenously injected cells was relatively limited, as cells were only 
found in the marrow space of the IVD and not in the NP, AF, or CEP. Moreover, only 
direct disc injection prevented a significant loss of the discs’ height. However, both deliv-
ery methods enhanced GAG production and upregulated the gene expression of ACAN 
relative to controls. The investigators suggested that these anabolic findings were likely 
due to paracrine effects caused by the MSCs [100]. Beneficial effects of systemically deliv-
ered MSCs were also found by Cunha et al. [101]. They assessed the impact of intrave-
nously injected MSCs on a rat IVD lesion model. Based on IVD height index and histolog-
ical grading, they concluded that transplanting MSCs 24 h after the initiation of an IVD 
injury leads to significantly less herniation and IDD than the injection of dermal fibro-
blasts, which were used as control. Furthermore, they highlighted the systemic immuno-
modulatory effect of injected MSCs represented by an upregulation of the cytokines IL-2, 
IL-4, IL-6, and IL-10 and a downregulation of IL-13 as well as TNF-α. Nonetheless, they 
dismissed the opportunity to track the injected cells and to confirm their presence at the 
damaged IVD. Consequently, this would have created a direct correlation between the 
homing properties of MSCs and their role in IVD regeneration. A similar approach was 
also carried out by Sakai et al. [92]. Here, they harvested bone marrow-derived green flu-
orescent protein (GFP)-expressing cells from mice and injected them into the tail vein of 
the host mice, which had been subjected to bone marrow irradiation and IDD. The inves-
tigators showed that only a limited number of injected cells migrated into the IVD, 
whereas most cells were found in the peripheral bone marrow and the CEP’s vascular 
canals. However, there was a clear relation between the severity of the induced IDD and 
the amount of recruited cells [92]. The data from Sakai et al. point out the difficulty of the 
cells to migrate into the IVD, as healthy IVDs are usually completely avascular, whereby 
the capillaries terminate at the CEPs and outermost AF [102,103]. Nevertheless, degener-
ated IVDs are also reported to induce vascular ingrowth in the outer layers of the AF [22]. 
Even though this neovascularization is seen as a pathological process in the IVD, it could 
potentially facilitate MSCs to reach the damaged sites and promote regeneration. How-
ever, this hypothesis has yet to be proven. 
In order to identify how obstructive CEPs are for MSCs to home into the inner IVD, 
bovine IVDs with and without CEPs were cultured in a bioreactor system under physio-
logical and pathological conditions in a study by Illien-Jünger et al. [93]. Interestingly, 
removal of the CEPs did not foster MSC migration, and MSCs were located mainly in the 
NP of degenerated IVDs. Moreover, Boyden chamber assays confirmed the chemoattrac-
tive properties of the culture medium, which was collected from degenerated IVDs. The 
higher the proportion of medium from degenerated IVDs, the greater the chemoattractive 
response of the MSCs. 
The ability of stem cells to move through the endplate into the IVD and affect IVD 
metabolism was confirmed by Pereira et al. [104]. They used nucleotomized bovine IVDs 
and seeded human MSCs on the endplate surface. After up to three weeks of ex vivo cul-
ture, the group discovered that MSCs successfully migrated from the CEP into the inner 
IVD as far as the lesion area. Furthermore, cell migration significantly upregulated the 
expression of matrix proteins ACAN and COL2. Additionally, migration enhanced the 
production of growth factors, including fibroblast growth factor-6 (FGF-6) and 7 (FGF-7), 
insulin-like growth factor-1 receptor (IGF-1sR), and platelet-derived growth factor recep-
tor (PDGF-R). 
Another approach to investigate the influence of homed MSCs on degenerated IVDs 
was taken by Wangler et al. In brief, human MSCs were seeded on bovine whole IVDs 
and on either healthy, traumatic, or degenerated human IVD tissues [105]. After a period 
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of MSC homing into the IVDs, they evaluated the cells’ effect on the host’s Tie2 progenitor 
cell populations, the IVD cell survival, and proliferation. The study showed that homed 
stem cells enhanced the proportion of Tie2-positive cells in both bovine and human IVD 
samples. Additionally, a proliferative response of the IVD cells was observed, and finally, 
MSC homing reduced the fraction of dead cells in the IVD. Table 3 summarizes the recent 
studies related to the homing capabilities of MSCs into the IVD. 
However, to verify the potential of MSCs homing into a damaged or degenerated 
IVD and to assess the pathbreaking aspect of this innovative treatment for cell-based ap-
proaches to regenerate the IVD, preclinical in vivo studies on larger animals and clinical 
trials need to be performed. These trials will reveal how efficiently MSCs can be recruited 
from their source of production and storage, their stem cell niche within the IVD, or 
through intravenous cell injection. Furthermore, in the case of successful homing, the 
homed MSCs would have to prove their superiority against direct cell injection into the 
IVD. Only if the migrated cells can reduce LBP and promote IVD regeneration, clinical 
translation will be successful. Nevertheless, the advantage of MSC homing over direct 
injection into the IVD seems obvious, namely that no further damage to the IVD is being 
caused by needle puncture. 
Table 3. Recent studies related to the homing capabilities of MSCs into the IVD. 
Species Study 
Type 
Cell Types Outcomes References 
Human in vitro BM MSCs Growth factors and chemokines such as IGF-1, PDGF-AB, 
RANTES, and SDF-1 showed a chemoattractive effect on MSCs. 
[95] 
Bovine IVDs and 
human MSCs ex vivo BM MSCs 
An intradiscal injectable hydrogel-based on hyaluronan-poly(N-
isopropylacrylamide) and supplemented with SDF-1 showed a 
chemoattractive effect on MSCs. 
[97] 
Bovine IVDs and 
human MSCs ex vivo BM MSCs 
The concentration of RANTES was significantly elevated in the 
medium of induced degenerated IVDs; RANTES may be a key 
chemoattractant for MSCs in the IVD. 
[98] 
Bovine IVDs and 
human MSCs ex vivo BM MSCs 
MSC subpopulations positive for CD146 were associated with a 
greater homing potential but produced a weaker regenerative re-









Intravenously injected MSCs showed limited ability to home into 
a degenerated IVD, but they upregulated GAG and ACAN. 
[100] 
Murine in vivo BM MSCs Intravenously injected MSCs significantly decreased IVD herni-ation and induced an immunomodulatory effect. [101] 
Murine in vivo BM MSCs 
Only a limited number of intravenously injected MSCs migrated 
to a degenerated IVD. However, the more serious the injury, the 
more cells were recruited. 
[92] 
Bovine IVDs and 
human MSCs 
ex vivo BM MSCs 
Greater MSC homing occurred with degenerated IVDs than 
healthy samples, and IGF-1-transduced MSCs significantly in-
creased the proteoglycan synthesis. 
[93] 
Bovine IVDs and 
human MSCs 
ex vivo BM MSCs 
MSCs seeded on the endplate’s surface of nucleotomized IVDs 





ex vivo BM MSCs 
Homed MSCs increased the fraction of Tie2-positive IVD cells, 
enhanced IVD cell proliferation, and reduced the fraction of dead 
cells in the IVD. 
[105] 
Abbreviations: IVD = intervertebral disc, BM = bone marrow, MSC = mesenchymal stromal cells, MPSC = multipotent stem 
cells, IGF-1 = insulin-like growth factor 1, PDGF-AB = platelet-derived growth factor -AB, SDF-1 = stromal cell-derived 
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factor 1, CD146 = cluster of differentiation 146, GAG = glycosaminoglycan, ACAN = aggrecan, ECM = extracellular matrix, 
and Tie2 = angiopoietin-1 receptor. 
3. Limitations of MSC-Based IVD Regeneration 
Despite the extensive number of studies and clinical trials that have been carried out 
in recent years, MSC-based cell therapy comes with some major drawbacks. As an exam-
ple, there is an exponential decline of the MSC reservoir in the bone marrow with aging 
when autologous cell transplantation was considered [45]. A newborn has approximately 
one MSC per 10,000 bone marrow cells. As a teenager, the reservoir is already reduced to 
one MSC per 100,000 bone marrow cells, and as an elderly person aged approximately 80 
years old, the fraction of MSCs in marrow cells decreases to 1 per 2 million [45]. As a 
matter of fact, this notable reduction in MSC titers creates a dilemma, as middle-aged and 
elderly people are usually the ones most affected by IDD and LBP, though they are usually 
the ones to show a relatively small number of MSCs in case of autologous cell therapy 
[106]. While this can be partially counteracted with ex vivo cell expansion, MSCs are 
known to lose their differential potential overtime with increasing cell population dou-
bling levels and increasing age [107,108]. Furthermore, the inter-donor variability in MSC 
quality and quantity has to be considered [109]. Alternatively, the use of allogeneic cells 
from younger donors is a valuable option. In this case, however, the question arises of 
how easy and feasible it is to find enough potential donors. Another obstacle for successful 
cell therapy with MSCs is the previously described harsh microenvironment of an IVD 
[16]. It is yet unknown how well bone marrow-derived MSCs can adapt to this environ-
ment and survive over a long period. Nevertheless, hydrogels could be a promising solu-
tion to overcome this issue [110]. 
4. Conclusions 
For years, spinal fusion has been considered the “gold standard” to surgically treat 
chronic discogenic LBP. However, because the technique intends to replace the IVD rather 
than regenerate the existing IVD, great efforts have been made to develop more biological 
therapies. Thereby, the application of MSC-based therapies has been placed into the spot-
light. Many preclinical in vitro studies have been carried out to direct these cells into an 
IVD cell-like phenotype using exogenously added growth factors, thereby making the 
MSCs increasingly compatible and efficient for cell-based therapy. In ex vivo and in vivo 
studies, hydrogels and scaffolds transplanted with embedded MSCs have also shown 
promise. Even if the ideal biomaterial for IVD regeneration is yet to be found, novel bio-
materials mimic the IVD tissue, providing adequate structural and biochemical support 
for MSCs. Finally, multiple clinical studies have reported efficient amelioration of LBP 
and a general improvement in the Pfirrmann grade following intradiscal MSC injection. 
However, long-term data are still missing that show how well injected bone marrow-de-
rived MSCs can adapt to the harsh environment of an IVD and exhibit an actual regener-
ative effect. 
In the past decade, alternatives to intradiscal cell injection have been sought. Proba-
bly the most promising approach seems to take advantage of MSC homing capabilities. In 
vitro cell and organ culture studies have shown that MSCs can be attracted by chemokines 
and growth factors released by degenerated IVDs, indicating that this strategy can poten-
tially be used for IVD regeneration. Nevertheless, some controversies remain about the 
efficiency of exogenously administered MSCs to home in a degenerated IVD in vivo. 
While some studies claim that no or only a minimal number of administered MSCs can 
migrate into the IVD and therefore only have a limited regenerative potential, others sug-
gest that already low numbers of migrated cells are sufficient to exert a regenerative effect. 
In general, the respective studies agree that homed MSCs positively affect degenerated 
IVDs, including immunomodulatory effects, an upregulation of anabolic genes, cell sur-
vival and proliferation, and the production of growth factors. Nonetheless, there is still a 
lack of preclinical in vivo studies on large animals, and ultimately clinical trials, on the 
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ability of MSCs to home into degenerated or damaged IVDs and consequently their im-
pact on IVD regeneration. 
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ACAN Aggrecan 
AF Annulus Fibrosus 
BDI Beck Depression Inventor 
BMP2 Bone Morphogenetic Protein 2 
CA12 Carbonic Anhydrase 12 
CD Cluster of Differentiation 
CEP Cartilaginous Endplate 
CFU-F Colony Forming Unit-Fibroblasts 
COL1 Collagen Type I 
COL2 Collagen Type II 
CTGF Connective Tissue Growth Factor 
CXCR4 C-X-C Chemokine Receptor Type 4 
DALY Disability-Adjusted Life-Years 
FGF Fibroblast Growth Factor 
FOX Forkhead Box 
GAG Glycosaminoglycan 
GD2 Disialoganglioside 2 
GDF Growth/Differentiation Factor 
IDD Intervertebral Disc Degeneration 
IGF-1 Insulin-Like Growth Factor 1 
IGF-1sR Insulin-Like Growth Factor 1 Receptor 
IL-1β Interleukin-1β 
iPSC Induced Pluripotent Stem Cell 
IVD Intervertebral Disc 
KRT Cytokeratin 
LBP Low Back Pain 
MDC Macrophage-Derived Chemokine 
MRI Magnetic Resonance Imaging 
MSC Mesenchymal Stromal Cell 
NP Nucleus Pulposus 
NSAID Non-Steroidal Anti-Inflammatory Drug 
ODI Oswestry Disability Index 
PAX Paired Box 
PCL Polycaprolacton 
PDGF-R Platelet-Derived Growth Factor Receptor 
PPI Present Pain Intensity 
SANE Single Assessment Numeric Evaluation 
SDF-1 Stromal Cell-Derived Factor 1 
SHH Sonic Hedgehog Signaling Molecule 
SOX SRY-Box Transcription Factor 
TGF-β3 Transforming Growth Factor β3 
Tie2 Angiopoietin-1 Receptor 
TNF-α Tumor Necrosis Factor α 
VAS Visual Analogue Scale 
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